AqVida offering out-licensing opportunities for oncology at CPhI 2014
Press Release | AqVida GmbH
SEPTEMBER 16, 2014
Hamburg, Germany: – German oncology specialist, AqVida, will make a return to Europe’s foremost pharmaceutical event, CPhI Worldwide, in Paris next month with a range of out-licensing and alternative supply opportunities for its range of generic finished dosage forms.
The Hamburg-based laboratory and manufacturer hopes to build on the success of its first CPhI appearance as an exhibitor in Frankfurt Messe last year.
“CPHI Worldwide is the leading pharma event for us,” said AqVida CEO Wolfgang Heinze.
“Only during CPHI can you manage to bring all your business partners together at one table, as well as make interesting new contacts. Last year we generated a series interesting business opportunities with companies who found us in the exhibitor guide,” recalled Mr. Heinze.
The AqVida display at Booth 4C61SSP in Hall 4 at Paris Nord Villepinte will showcase the company’s entire portfolio of proven oncology injectables, including Paclitaxel, Oxaliplatin, Docetaxel and Epirubicin.
“We have several opportunities available for out-licensing some of our products, depending on client portfolio and market stance,” Mr. Heinze noted.
He said AqVida were particularly keen to talk to pharmaceutical companies looking to bring German-quality GMP certified oncology products to their markets. The company was actively seeking professional partners familiar with registration procedures, market needs and distribution channels who were looking to build long-term relationships.
“A growing number of pharmaceutical companies especially in Asia, Africa and South America are looking for alternatives in generic oncologic supply as quality requirements become ever more stringent, in Europe and beyond. AqVida is able to match these needs with EU quality products at a competitive price level. While AqVida is a full service pharmaceutical company, we are very flexible and quick in finding optimum solutions for our clients,” said Mr. Heinze.
AqVida is a German pharmaceutical company specializing in the development, registration and distribution of finished dosage forms mainly in the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in the development, registration and supply of generic oncology products and biosimilars has made the company a leading partner in the pharmaceutical industry. The Hamburg-based company also has offices in Oberhaching, Bavaria and in Hangzhou, China.
AqVida works alongside some of the major companies in the market of oncology products. Together with its partners AqVida has achieved substantial development and growth with its oncology portfolio.
As a pharmaceutical company AqVida fulfills all client requirements from API sourcing up to EU market release for the finished product. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.
Products are sold under the AqVida brand or those of its partners’ in the EU and other markets.
AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organisation, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.
About CPhl Worldwide
CPhI Worldwide bills itself as ‘the number one Pharma sourcing event’, offering delegates opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.
The 2014 event is being held 7-9 October 2014 at the Paris Nord Villepinte exhibition center and is expected to be the biggest CPhI Worldwide event to date, attracting more than 35,000 delegates from some 140 countries along with around 2,500 exhibitors.
The CPhl show is being held alongside three other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events.
The Pre-Connect Conference on October 6 comprises eight modules on current industry ‘hot topics’ from API sourcing to Trends in Oncology and offers specifically themed networking opportunities.
CPhl is staged by leading global B2B events organizer and publisher, UBM Live.
More information at http://www.cphi.com/europe/home
Wolfgang Heinze, CEO, AqVida GmbH
Tel: +49 40 380 37190
Click on AqVida offering out-licensing opportunities for oncology at CPhI 2014 for other information.
Click on AqVida to contact the company directly.